Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening

Sullivan, Francis Michael; Mair, Frances S.; Anderson, William; Chew, Cindy; Dorward, Alistair; Haughney, John; Hogarth, Fiona; Kendrick, Denise; Littleford, Roberta; McConnachie, Alex; McCowan, Colin; McMeekin, Nicola; Patel, Manish; Rauchhaus, Petra; Daly, Fergus; Ritchie, Lewis; Robertson, John; Sarvesvaran, Joseph; Sewell, Herbert; Taylor, Thomas; Treweek, Shaun; Vedhara, Kavita; Schembri, Stuart

Abstract

The role of biomarkers in risk-based early detection of lung cancer may enable screening to become cost effective and widely accessible. EarlyCDT-Lung is an example of such a blood-based autoantibody biomarker which may improve accessibility to Low dose Computed Tomography (LDCT) screening for those at highest risk. We randomized 12 208 individuals aged 50-75 at high risk of developing lung cancer to either the test or to standard clinical care. Outcomes were ascertained from Register of Deaths and Cancer Registry. Cox proportional hazards models were used to estimate the hazard ratio of the rate of deaths from all causes and lung cancer. Additional analyses were performed for cases of lung cancer diagnosed within two years of the initial test. After 5 years 326 lung cancers were detected (2.7% of those enrolled). The total number of deaths reported from all causes in the intervention group was 344 compared to 388 in the control group. There were 73 lung cancer deaths in the intervention arm and 90 in the controls (Adjusted HR 0.789 (0.636, 0.978). An analysis of cases of lung cancer detected within 2 years of randomization in the intervention group showed that there were 34 deaths from all causes and 29 from lung cancer. In the control group there were 56 deaths with 49 from lung cancer. In those diagnosed with lung cancer within 2 years of randomization the hazard ratio for all cause mortality was 0.615 (0.401,0.942) and for lung cancer 0.598 (0.378, 0.946).

Further large-scale studies of the role of biomarkers to target lung cancer screening, in addition to LDCT, are likely to provide additional value.

Citation

Sullivan, F. M., Mair, F. S., Anderson, W., Chew, C., Dorward, A., Haughney, J., Hogarth, F., Kendrick, D., Littleford, R., McConnachie, A., McCowan, C., McMeekin, N., Patel, M., Rauchhaus, P., Daly, F., Ritchie, L., Robertson, J., Sarvesvaran, J., Sewell, H., Taylor, T., …Schembri, S. (2025). Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening. PLoS ONE, 20(1), Article e0306163. https://doi.org/10.1371/journal.pone.0306163

• Journal Article Type: Article
• Acceptance Date: Nov 7, 2024
• Online Publication Date: Jan 8, 2025
• Publication Date: Jan 8, 2025
• Deposit Date: Nov 27, 2024
• Publicly Available Date: Nov 27, 2024
• Journal: PLOS ONE
• Electronic ISSN: 1932-6203
• Publisher: Public Library of Science
• Peer Reviewed: Peer Reviewed
• Volume: 20
• Issue: 1
• Article Number: e0306163
• DOI: https://doi.org/10.1371/journal.pone.0306163
• Keywords: Lung and intrathoracic tumors; Cancer detection and diagnosis; Cancer risk factors; Biomarkers; Cancer screening; Death rates; Cancer treatment; Blood
• Public URL: https://nottingham-repository.worktribe.com/output/42476699
• Publisher URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0306163